Residual: A phase 2a multi-center study of 18F-FDG PET, safety and tolerability of AZD0530 in mild Alzheimer#s disease

Pharmacology, Toxicology and Pharmaceutical Science

1. Tolerability 100%
2. Saracatinib 100%
3. Fluorodeoxyglucose F 18 100%
4. Polyethylene Terephthalate 100%
5. Diseases 100%
6. Placebo 22%
7. Controlled Clinical Trial 11%
8. Phosphotransferase Inhibitor 11%
9. Adverse Event 11%
10. Biological Marker 11%
11. Fluorodeoxyglucose 11%